Skip to content
10-K

Annual Report

NEXIEN BIOPHARMA, INC.

0001493152-24-041978

← back to feed
Filed
Oct 22, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Oct 22, 2024 70.77M sh
Shares Diluted FY 2024 · Jun 30, 2024 66.19M sh
Shares Diluted FY 2024 · Jun 30, 2023 62.33M sh
Operating Cash Flow FY 2024 · Jun 30, 2024 −$64.36K
Operating Cash Flow FY 2024 · Jun 30, 2023 −$81.75K
Cash And Equivalents FY 2024 · Jun 30, 2024 $4.18K
Cash And Equivalents FY 2024 · Jun 30, 2023 $35.15K
Stockholders Equity FY 2024 · Jun 30, 2024 −$361.25K
Stockholders Equity FY 2024 · Jun 30, 2023 −$252.01K
Stockholders Equity FY 2024 · Jun 30, 2022 −$117.61K
Current Liabilities FY 2024 · Jun 30, 2024 $365.43K
Current Liabilities FY 2024 · Jun 30, 2023 $295.13K
Total Liabilities FY 2024 · Jun 30, 2024 $365.43K
Total Liabilities FY 2024 · Jun 30, 2023 $295.13K
Current Assets FY 2024 · Jun 30, 2024 $4.18K
Current Assets FY 2024 · Jun 30, 2023 $43.13K
Total Assets FY 2024 · Jun 30, 2024 $4.18K
Total Assets FY 2024 · Jun 30, 2023 $43.13K
Eps Diluted FY 2024 · Jun 30, 2024 $0.00
Eps Diluted FY 2024 · Jun 30, 2023 −$0.01
Eps Basic FY 2024 · Jun 30, 2024 $0.00
Eps Basic FY 2024 · Jun 30, 2023 −$0.01
Sga Expense FY 2024 · Jun 30, 2024 $122.17K
Sga Expense FY 2024 · Jun 30, 2023 $246.95K
Rd Expense FY 2024 · Jun 30, 2024 $0
Rd Expense FY 2024 · Jun 30, 2023 $0
Net Income FY 2024 · Jun 30, 2024 −$239.11K
Net Income FY 2024 · Jun 30, 2023 −$361.9K
Operating Income FY 2024 · Jun 30, 2024 $11.53M